Reply to Gan <i>et al.</i>, to Calzetta <i>et al.</i>, and to Poor

Anzueto, Antonio; Barjaktarevic, Igor Z.; Siler, Thomas M.; Rheault, Tara; Bengtsson, Thomas; Rickard, Kathleen; Sciurba, Frank

doi:10.1164/rccm.202309-1657le

Am J Respir Crit Care Med

2024

DOI: 10.1164/rccm.202309-1657le

|View full text |Cite

Reply to Gan et al., to Calzetta et al., and to Poor

Antonio Anzueto,

Igor Z. Barjaktarevic,

Thomas M. Siler

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This report summarizes the results of two phase III clinical trials of nebulized, twice-daily ensifentrine 3 mg evaluated in the 24-week ENHANCE (Ensifentrine as a Novel Inhaled Nebulized COPD Therapy)-1 ( 34 ) (with 48-wk safety subset) and ENHANCE-2 ( 35 ) trials in patients with moderate to severe COPD. Some of the results of these trials were previously reported in the form of abstracts ( 36 – 42 ).…”

mentioning

confidence: 99%

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Anzueto

Siler

Rheault³

et al. 2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Rationale Ensifentrine is a novel, selective, dual phosphodiesterase (PDE)3 and PDE4 inhibitor with bronchodilator and antiinflammatory effects. Replicate phase III trials of nebulized ensifentrine were conducted (ENHANCE-1 and ENHANCE-2) to assess these effects in patients with chronic obstructive pulmonary disease (COPD). Objectives To evaluate the efficacy of ensifentrine compared with placebo for lung function, symptoms, quality of life, and exacerbations in patients with COPD. Methods These phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled trials were conducted between September 2020 and December 2022 at 250 research centers and pulmonology practices in 17 countries. Patients aged 40–80 years with moderate to severe symptomatic COPD were enrolled. Measurements and Main Results Totals of 760 (ENHANCE-1) and 789 (ENHANCE-2) patients were randomized and treated, with 69% and 55% receiving concomitant long-acting muscarinic antagonists or long-acting β 2 -agonists, respectively. Post-bronchodilator FEV 1 percentage predicted values were 52% and 51% of predicted normal. Ensifentrine treatment significantly improved average FEV 1 area under the curve at 0–12 hours versus placebo (ENHANCE-1, 87 ml [95% confidence interval, 55, 119]; ENHANCE-2, 94 ml [65, 124]; both P < 0.001). Ensifentrine treatment significantly improved symptoms (Evaluating Respiratory Symptoms) and quality of life (St. George’s Respiratory Questionnaire) versus placebo at Week 24 in ENHANCE-1 but not in ENHANCE-2. Ensifentrine treatment reduced the rate of moderate or severe exacerbations versus placebo over 24 weeks (ENHANCE-1, rate ratio, 0.64 [0.40, 1.00]; P = 0.050; ENHANCE-2, rate ratio, 0.57 [0.38, 0.87]; P = 0.009) and increased time to first exacerbation (ENHANCE-1, hazard ratio, 0.62 [0.39, 0.97]; P = 0.038; ENHANCE-2, hazard ratio, 0.58 [0.38, 0.87]; P = 0.009). Adverse event rates were similar to those for placebo. Conclusions Ensifentrine significantly improved lung function in both trials, with results supporting exacerbation rate and risk reduction in a broad COPD population and in addition to other classes of maintenance therapies. Clinical trial registered with www.clinicaltrials.gov and EudraCT (ENHANCE-1, www.clinicaltrials.gov identifier NCT04535986, EudraCT identifier 2020-002086-34; ENHANCE-2, www.clinicaltrials.gov identifier NCT04542057, EudraCT identifier 2020-002069-32).

show abstract

mentioning

confidence: 99%

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Anzueto

Siler

Rheault³

et al. 2023

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease

Cazzola,

Calzetta,

Rogliani

et al. 2024

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Reply to Gan et al., to Calzetta et al., and to Poor

Cited by 2 publications

References 14 publications

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease

Contact Info

Product

Resources

About